Up until now, attention has been highly fixated on ‘Medical cannabis’. Meanwhile Pharmaceutical Cannabinoids have made incredible progress, now academia and industry must unite to advance further. By providing the inaugural International Cannabinoid-Derived Pharmaceuticals Summit, we have created this opportunity.

Issues include formulating unique compounds that achieve required responses, that can be delivered effectively. Many also still face problems designing reliable clinical trials in a frequently changing regulatory environment. We’ll be sharing and discussing these issues in depth with industry leaders such as Adi Zulloff-Shani of Therapix and Catherine Jacobson of Tilray.